U.S. SEVERE ORAL MUCOSITIS MARKET ANALYSIS

Market Challenges And Opportunities

U.S. Severe Oral Mucositis Market– Impact of Coronavirus (COVID-19) Pandemic

The coronavirus (COVID-19) pandemic and lockdown in various countries across the globe have impacted the financial status of businesses in all sectors. Private healthcare sector is one of the sectors, which is majorly impacted by the COVID-19 pandemic. Moreover, coronavirus pandemic has negatively impacted the development, production, and supply of pharmaceutical products, and affected the growth of several oral mucositis medication businesses of various companies across the regions such as North America (U.S.). COVID-19 pandemic led to an unprecedented lockdown in several countries such as U.S. This lockdown resulted in closure of industrial establishments except manufacturing of essential commodities and disruption in supply chain of the pharmaceutical products. Thus, COVID-19 pandemic has affected the economy in three main ways; 1) by directly affecting the production and demand; 2) by creating disruptions in distribution channels; and 3) by its financial impact on firms and financial markets. Supply chain and manufacturing activities in India, Italy, Spain, the U.K., and the U.S. have been disrupted due to lockdowns implemented by various governments in the past few months, while countries such as Brazil, France, Russia, Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of drug products. Due to severe shortage of medical resources at the front line, only patients diagnosed with serious conditions are being hospitalized. Unfortunately, the pathogenic mechanism of the virus has not been identified completely, even though, vaccines and drugs are being manufactured by various companies for prevent and treat COVID-19. The COVID-19 pandemic has impacted the global economy and in turn, the U.S. severe oral mucositis market. Quarantine, traveling constraints, and social distancing measures are likely to cause a steep decline in business and consumer spending until the end of the first quarter of 2021.

U.S. Severe Oral Mucositis Market: Restraint

The major factors that hinder growth of the U.S. severe oral mucositis market include high incremental cost associated with severe oral mucositis in cancer patients. For instance, according to the report published by Oxford University Press in 2019, patients undergoing chemotherapy and radiation therapy for the treatment of head and neck cancers have to pay incremental cost for the treatment of complications associated with the treatments such as severe oral mucositis. According to the same source, patients have to pay extra US$ 5,000– 30,000 for the treatment of oral mucositis that was induced due to radiation therapy while patients had to pay US$ 3,700 per cycle for oral mucositis induced due to chemotherapy in the U.S. This treatment cost included hospitalization fees, medication cost (medications included are kepivance (Palifermin), analgesic drugs, and systemic infusions in severe cases, among others), and others.